

Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Growth 2024-2030

<https://marketpublishers.com/r/G7DFC0976D14EN.html>

Date: June 2024

Pages: 88

Price: US\$ 3,660.00 (Single User License)

ID: G7DFC0976D14EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent refers to an inactivated split influenza vaccine whose vaccine components include A (H3N2) subtype, A (H1N1) pdm09 subtype, and type B Victoria and Yamagata lines.

The global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industry Forecast” looks at past sales and reviews total world Influenza Vaccine (Split Virion), Inactivated, Quadrivalent sales in 2023, providing a comprehensive analysis by region and market sector of projected Influenza Vaccine (Split Virion), Inactivated, Quadrivalent sales for 2024 through 2030. With Influenza Vaccine (Split Virion), Inactivated, Quadrivalent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Influenza Vaccine (Split Virion), Inactivated, Quadrivalent industry.

This Insight Report provides a comprehensive analysis of the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Influenza Vaccine (Split Virion), Inactivated, Quadrivalent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an

accelerating global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent.

United States market for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Influenza Vaccine (Split Virion), Inactivated, Quadrivalent players cover Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Child

Adult

Elder

Segmentation by Application:

Hospital

Clinic

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Hualan Bacterin

Sinovac Biotech

Sanofi

CSL Seqirus

GSK

Adimmune

Sinopharm

Jiangsu GDK Biotechnology

Abbott

Ab&B BIO-TECH

Key Questions Addressed in this Report

What is the 10-year outlook for the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market?

What factors are driving Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market opportunities vary by end market size?

How does Influenza Vaccine (Split Virion), Inactivated, Quadrivalent break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Sales 2019-2030

2.1.2 World Current & Future Analysis for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Geographic Region, 2019, 2023 & 2030

2.1.3 World Current & Future Analysis for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Country/Region, 2019, 2023 & 2030

2.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Segment by Type

2.2.1 Child

2.2.2 Adult

2.2.3 Elder

2.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type

2.3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)

2.3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue and Market Share by Type (2019-2024)

2.3.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Price by Type (2019-2024)

2.4 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.5 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application

2.5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Market Share by Application (2019-2024)

2.5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue and Market Share by Application (2019-2024)

2.5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Breakdown Data by Company

3.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Sales by Company (2019-2024)

3.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Company (2019-2024)

3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Revenue by Company (2019-2024)

3.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Company (2019-2024)

3.2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Company (2019-2024)

3.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Price by Company

3.4 Key Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Location Distribution

3.4.2 Players Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR INFLUENZA VACCINE (SPLIT VIRION), INACTIVATED, QUADRIVALENT BY GEOGRAPHIC REGION

4.1 World Historic Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Geographic Region (2019-2024)

4.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Sales by

Geographic Region (2019-2024)

4.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country/Region (2019-2024)

4.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Sales by Country/Region (2019-2024)

4.2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Revenue by Country/Region (2019-2024)

4.3 Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Growth

4.4 APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Growth

4.5 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Growth

4.6 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Growth

5 AMERICAS

5.1 Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country

5.1.1 Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024)

5.1.2 Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024)

5.2 Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024)

5.3 Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region

6.1.1 APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2019-2024)

6.1.2 APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2019-2024)

6.2 APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024)

6.3 APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Country

7.1.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024)

7.1.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024)

7.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024)

7.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Country

8.1.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024)

8.1.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024)

8.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024)

8.3 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

10.3 Manufacturing Process Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

10.4 Industry Chain Structure of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Distributors

11.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Customer

12 WORLD FORECAST REVIEW FOR INFLUENZA VACCINE (SPLIT VIRION), INACTIVATED, QUADRIVALENT BY GEOGRAPHIC REGION

12.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size Forecast by Region

12.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Forecast by Region (2025-2030)

12.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Forecast by Type (2025-2030)

12.7 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Hualan Bacterin

13.1.1 Hualan Bacterin Company Information

13.1.2 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.1.3 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Hualan Bacterin Main Business Overview

13.1.5 Hualan Bacterin Latest Developments

13.2 Sinovac Biotech

13.2.1 Sinovac Biotech Company Information

13.2.2 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.2.3 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Sinovac Biotech Main Business Overview

13.2.5 Sinovac Biotech Latest Developments

13.3 Sanofi

13.3.1 Sanofi Company Information

13.3.2 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.3.3 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 Sanofi Main Business Overview

13.3.5 Sanofi Latest Developments

13.4 CSL Seqirus

13.4.1 CSL Seqirus Company Information

13.4.2 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.4.3 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 CSL Seqirus Main Business Overview

13.4.5 CSL Seqirus Latest Developments

13.5 GSK

13.5.1 GSK Company Information

13.5.2 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.5.3 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 GSK Main Business Overview

13.5.5 GSK Latest Developments

13.6 Adimmune

13.6.1 Adimmune Company Information

13.6.2 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.6.3 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Adimmune Main Business Overview

13.6.5 Adimmune Latest Developments

13.7 Sinopharm

13.7.1 Sinopharm Company Information

13.7.2 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.7.3 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Sinopharm Main Business Overview

13.7.5 Sinopharm Latest Developments

13.8 Jiangsu GDK Biotechnology

13.8.1 Jiangsu GDK Biotechnology Company Information

13.8.2 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.8.3 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Jiangsu GDK Biotechnology Main Business Overview

13.8.5 Jiangsu GDK Biotechnology Latest Developments

13.9 Abbott

13.9.1 Abbott Company Information

13.9.2 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.9.3 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Abbott Main Business Overview

13.9.5 Abbott Latest Developments

13.10 Ab&B BIO-TECH

13.10.1 Ab&B BIO-TECH Company Information

13.10.2 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

13.10.3 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Ab&B BIO-TECH Main Business Overview

13.10.5 Ab&B BIO-TECH Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of Child
- Table 4. Major Players of Adult
- Table 5. Major Players of Elder
- Table 6. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024) & (K Units)
- Table 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)
- Table 8. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type (2019-2024) & (\$ million)
- Table 9. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type (2019-2024)
- Table 10. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Price by Type (2019-2024) & (US\$/Unit)
- Table 11. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale by Application (2019-2024) & (K Units)
- Table 12. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Market Share by Application (2019-2024)
- Table 13. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application (2019-2024) & (\$ million)
- Table 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2019-2024)
- Table 15. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Price by Application (2019-2024) & (US\$/Unit)
- Table 16. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Company (2019-2024) & (K Units)
- Table 17. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Company (2019-2024)
- Table 18. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Company (2019-2024) & (\$ millions)
- Table 19. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Company (2019-2024)

Table 20. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Price by Company (2019-2024) & (US\$/Unit)

Table 21. Key Manufacturers Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Producing Area Distribution and Sales Area

Table 22. Players Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Products Offered

Table 23. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Region (2019-2024) & (K Units)

Table 27. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share Geographic Region (2019-2024)

Table 28. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 29. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Geographic Region (2019-2024)

Table 30. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country/Region (2019-2024) & (K Units)

Table 31. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country/Region (2019-2024)

Table 32. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country/Region (2019-2024) & (\$ millions)

Table 33. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country/Region (2019-2024)

Table 34. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)

Table 35. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country (2019-2024)

Table 36. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024) & (\$ millions)

Table 37. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024) & (K Units)

Table 38. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024) & (K Units)

Table 39. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2019-2024) & (K Units)

Table 40. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market

Share by Region (2019-2024)

Table 41. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2019-2024) & (\$ millions)

Table 42. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024) & (K Units)

Table 43. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024) & (K Units)

Table 44. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)

Table 45. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024) & (\$ millions)

Table 46. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024) & (K Units)

Table 47. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024) & (K Units)

Table 48. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)

Table 49. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2024)

Table 50. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024) & (K Units)

Table 51. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024) & (K Units)

Table 52. Key Market Drivers & Growth Opportunities of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Table 53. Key Market Challenges & Risks of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Table 54. Key Industry Trends of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Table 55. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Distributors List

Table 58. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Customer List

Table 59. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Region (2025-2030) & (K Units)

Table 60. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 61. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Country (2025-2030) & (K Units)

Table 62. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 63. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Region (2025-2030) & (K Units)

Table 64. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 65. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Country (2025-2030) & (K Units)

Table 66. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 67. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Country (2025-2030) & (K Units)

Table 68. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 69. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Type (2025-2030) & (K Units)

Table 70. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 71. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Forecast by Application (2025-2030) & (K Units)

Table 72. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 73. Hualan Bacterin Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 74. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 75. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 76. Hualan Bacterin Main Business

Table 77. Hualan Bacterin Latest Developments

Table 78. Sinovac Biotech Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 79. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 80. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 81. Sinovac Biotech Main Business

Table 82. Sinovac Biotech Latest Developments

Table 83. Sanofi Basic Information, Influenza Vaccine (Split Virion), Inactivated,

Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 84. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 85. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 86. Sanofi Main Business

Table 87. Sanofi Latest Developments

Table 88. CSL Seqirus Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 89. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 90. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 91. CSL Seqirus Main Business

Table 92. CSL Seqirus Latest Developments

Table 93. GSK Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 94. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 95. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 96. GSK Main Business

Table 97. GSK Latest Developments

Table 98. Adimmune Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 99. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 100. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 101. Adimmune Main Business

Table 102. Adimmune Latest Developments

Table 103. Sinopharm Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 104. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 105. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 106. Sinopharm Main Business

Table 107. Sinopharm Latest Developments

Table 108. Jiangsu GDK Biotechnology Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 109. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 110. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 111. Jiangsu GDK Biotechnology Main Business

Table 112. Jiangsu GDK Biotechnology Latest Developments

Table 113. Abbott Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 114. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 115. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 116. Abbott Main Business

Table 117. Abbott Latest Developments

Table 118. Ab&B BIO-TECH Basic Information, Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturing Base, Sales Area and Its Competitors

Table 119. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolios and Specifications

Table 120. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 121. Ab&B BIO-TECH Main Business

Table 122. Ab&B BIO-TECH Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
- Figure 2. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country/Region (2023)
- Figure 10. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Child
- Figure 12. Product Picture of Adult
- Figure 13. Product Picture of Elder
- Figure 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type in 2023
- Figure 15. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type (2019-2024)
- Figure 16. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumed in Hospital
- Figure 17. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Hospital (2019-2024) & (K Units)
- Figure 18. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumed in Clinic
- Figure 19. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Clinic (2019-2024) & (K Units)
- Figure 20. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sale Market Share by Application (2023)
- Figure 21. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application in 2023
- Figure 22. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Company

in 2023 (K Units)

Figure 23. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Company in 2023

Figure 24. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Company in 2023 (\$ millions)

Figure 25. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Company in 2023

Figure 26. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Geographic Region (2019-2024)

Figure 27. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Geographic Region in 2023

Figure 28. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales 2019-2024 (K Units)

Figure 29. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue 2019-2024 (\$ millions)

Figure 30. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales 2019-2024 (K Units)

Figure 31. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue 2019-2024 (\$ millions)

Figure 32. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales 2019-2024 (K Units)

Figure 33. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue 2019-2024 (\$ millions)

Figure 34. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales 2019-2024 (K Units)

Figure 35. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue 2019-2024 (\$ millions)

Figure 36. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country in 2023

Figure 37. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2024)

Figure 38. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)

Figure 39. Americas Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2019-2024)

Figure 40. United States Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 41. Canada Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 42. Mexico Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 43. Brazil Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 44. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Region in 2023

Figure 45. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Region (2019-2024)

Figure 46. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)

Figure 47. APAC Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2019-2024)

Figure 48. China Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 49. Japan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 50. South Korea Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 51. Southeast Asia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 52. India Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 53. Australia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 54. China Taiwan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 55. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country in 2023

Figure 56. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2024)

Figure 57. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)

Figure 58. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2019-2024)

Figure 59. Germany Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 60. France Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 61. UK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue

Growth 2019-2024 (\$ millions)

Figure 62. Italy Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue

Growth 2019-2024 (\$ millions)

Figure 63. Russia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue

Growth 2019-2024 (\$ millions)

Figure 64. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country (2019-2024)

Figure 65. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)

Figure 66. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2019-2024)

Figure 67. Egypt Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue

Growth 2019-2024 (\$ millions)

Figure 68. South Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 69. Israel Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 70. Turkey Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 71. GCC Countries Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth 2019-2024 (\$ millions)

Figure 72. Manufacturing Cost Structure Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in 2023

Figure 73. Manufacturing Process Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Figure 74. Industry Chain Structure of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Figure 75. Channels of Distribution

Figure 76. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Forecast by Region (2025-2030)

Figure 77. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share Forecast by Region (2025-2030)

Figure 78. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share Forecast by Type (2025-2030)

Figure 79. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share Forecast by Type (2025-2030)

Figure 80. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share Forecast by Application (2025-2030)

Figure 81. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue

Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G7DFC0976D14EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7DFC0976D14EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

